NO962162L - Dipeptider som bevirker frigjöring av veksthormon - Google Patents
Dipeptider som bevirker frigjöring av veksthormonInfo
- Publication number
- NO962162L NO962162L NO962162A NO962162A NO962162L NO 962162 L NO962162 L NO 962162L NO 962162 A NO962162 A NO 962162A NO 962162 A NO962162 A NO 962162A NO 962162 L NO962162 L NO 962162L
- Authority
- NO
- Norway
- Prior art keywords
- growth hormone
- dipeptides
- pct
- hormone release
- cause growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Forbindelser med formel 1 hvor er veksthormon-frigjørende peptid-mimetika som er anvendelige ved behandling og forebyggelse av osteoporose. Z er -COCR1R2CLCOANR4R5; L er NR8, O eller CH2; W er hydrogen, eller, i kombinasjon med X, en benzokondensasjon hvor W og X er koblet sammen til en fenylring som eventuelt er substituert med en til tre substituenter uavhengig av hverandre, valgt fra R3*, T-R3b og R12; Y er hydrogen, C,-C8-alkyl, C4-Ci0-cykloalkyl, aryl-K-, fenyl-{Ci-C<ralkyl)-K- eller tienyl-fCi-Cs-alkyO-K-, hvor hver ring eventuelt er substituert med en til tre substituenter uavhengig av hverandre valgt fra R3", R3b og R12, hvor K er en binding, O, S(0)m eller NR21. X er OR2. R2. ^2¿M¿N¿Aryl 9 N¿C----- 9 .o-c¿ eller eller X i kombinasjon med W, er en benzokondensasjon, hvor W og X er bundet sammen til en fenylring som eventuelt er substituert med en til tre substituenter uavhengig av hverandre, valgt fra R3", -T-R* og R12; R1 er Ci-Cio-alkyl, aryl, aryHd-Cs-alkyl) og eller Ci-Cs-alkyl-K'-Ci-C5-alkyl, aryHCo-Cj-alkyO-K^d-Cs-alkyl), (C3-C7)-cykloalkyl- (CrCs-alkylJ-K^d-Cs-alkyl), hvor K1 er O, S(0)m. N(R2)C(0), C(0)N(R2), OC(0), C(0)0, -CR2=CR2- eller -CsC-, hvor arylgruppene er definert nedenfor og RJ samt alkylgruppene kan være ytterligere substituert med 1-5 halogenatomer, SfOJmR2*. 1 til 3 av OR2* eller C(O)OR2* og arylgruppene kan være ytterligere substituert med fenyl, fenoksy, arylalkyloksy, halogenfenyl, 1 til 3 av Ci-Cs-alkyl, 1 til 3 halogenatomer, 1 til 2 av OR2, metylendioksy, S(0)mR2,1 til 2 av CF3, OCF3, nitro, N(R2)(R2), N(R2)C(0)(R2), C(0)OR2, C{0)N{R2)(R2), S02N(R2)R2), N{R2)S02-aryl eller N(R2)SO2R2; R2e er hydrogen, Ct-C6-alkyl, C3-C7-cykloalkyl og kan være forbundet med R1 for å danne en C3-C8-ring som eventuelt innbefatter oksygen, svovel eller NR2"; R2 er hydrogen, Ct-Ce-alkyl, C3-Crcykloalkyl, Ci-Ce-halogenert alkyl; R21 er hydrogen eller Ci-Cs-alkyl; R2b er hydrogen-Ci-Ca-alkyl, C,-C8-halogenert alkyl, C3-C«-cykloalkyl, alkylaryl eller aryl; R31 er H, F, Cl, Br, l, OCF3, OCF2H, CH3, OCH3 eller CF3; R12 er H, F, Cl, Br, l. OCF3| OCF2H, CH3, OCH3 eller CF3; T er en binding eller utgjør fenyl eller en 5- eller 6-leddet heterocyklus som inneholder 1 til 3 heteroatomer valgt fra nitrogen, svovel eller oksygen, og som hver : eventuelt er substituert med en til tre substituenter valgt fra F, Cl, Br, l, CH3, OCH3, OCF3 og CF3; R* er hydrogen, CONR8R9, S02NRV, COOH, COO(C,-C«)-alkyl, NR2S02R9. NR2CONRV, NR2S02NR'R9, NR2C(0)R9, imidazolyl, tiazolyl eller tetrazolyl; R4 og R5 er uavhengig av hverandre, hydrogen, Ci-C6-alkyl, substituert Ci-Cs- alkyl, hvor subslituentene kan være 1 til 5 halogenatomer, 1 til 3 hydroksy, 1 til 3 C,-Cia-alkanoyloksy, 1 til 3 Ci-Ce-alkoksy, fenyl, fenoksy, 2-furyl, Ci-Ce- , alkoksykarbonyl, S(0)m(C,-C6-alkyl); eller R4 og R5 sammen utgjør -(CH2)rL.(CH2),-, hvor L. er C(R2)j, S(O)m eller N(R2), r og s er uavhengig av hverandre, 1 til 3 og R2 er som definert ovenfor; R9 er hydrogen eller d-Ca-alkyl og kan være forbundet med R2c for å danne en C3-C8-ring;
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1995/000410 WO1996038471A1 (en) | 1995-05-29 | 1995-05-29 | Dipeptides which promote release of growth hormone |
Publications (2)
Publication Number | Publication Date |
---|---|
NO962162D0 NO962162D0 (no) | 1996-05-28 |
NO962162L true NO962162L (no) | 1996-12-02 |
Family
ID=11004334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO962162A NO962162L (no) | 1995-05-29 | 1996-05-28 | Dipeptider som bevirker frigjöring av veksthormon |
Country Status (15)
Country | Link |
---|---|
US (1) | US5936089A (no) |
EP (1) | EP0828754B1 (no) |
JP (1) | JP3133073B2 (no) |
KR (1) | KR960041192A (no) |
CN (1) | CN1143647A (no) |
AT (1) | ATE288444T1 (no) |
AU (1) | AU5455496A (no) |
CA (1) | CA2220055C (no) |
DE (1) | DE69533991T2 (no) |
ES (1) | ES2235171T3 (no) |
FI (1) | FI974368A (no) |
IL (1) | IL118330A0 (no) |
MX (1) | MX9709278A (no) |
NO (1) | NO962162L (no) |
WO (1) | WO1996038471A1 (no) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9612276D0 (en) * | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
US5804578A (en) * | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US6329342B1 (en) | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
US6240161B1 (en) * | 1997-09-25 | 2001-05-29 | Siemens Medical Systems, Inc. | Multi-leaf collimator constrained optimization of intensity modulated treatments |
ATE470671T1 (de) | 1998-01-16 | 2010-06-15 | Helsinn Therapeutics Us Inc | Verbindungen mit wachstumshormon-freisetzender eigenschaft |
SI1077941T1 (sl) * | 1998-05-11 | 2010-01-29 | Novo Nordisk As | Spojine, ki imajo lastnost sproščanja rastnega hormona |
US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
US6639076B1 (en) | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
US6194578B1 (en) * | 1998-11-20 | 2001-02-27 | Pfizer Inc. | Dipeptide derivatives |
DE19859684A1 (de) * | 1998-12-23 | 2000-06-29 | Bayer Ag | Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie neue, Fluor enthalende beta-Iminovinyl- und beta-Iminoethylbenzole |
CA2347671A1 (en) * | 1998-12-24 | 2000-07-06 | Dupont Pharmaceuticals Company | Succinoylamino benzodiazepines as inhibitors of a.beta. protein production |
EP1930021A3 (en) | 1999-02-18 | 2008-06-18 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
US6828331B1 (en) | 1999-02-19 | 2004-12-07 | Eli Lilly And Company | Growth hormone secretagogues |
US6696418B1 (en) * | 1999-09-01 | 2004-02-24 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
US20020016298A1 (en) * | 1999-09-01 | 2002-02-07 | Hay Bruce A. | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor |
US6960576B2 (en) * | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
CA2386517A1 (en) * | 1999-10-07 | 2001-04-12 | Takeda Chemical Industries, Ltd. | Amine derivatives |
WO2001027091A1 (en) | 1999-10-08 | 2001-04-19 | Du Pont Pharmaceuticals Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
JP2003523345A (ja) | 2000-02-17 | 2003-08-05 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Aβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環 |
WO2001074784A1 (en) | 2000-04-03 | 2001-10-11 | Dupont Pharmaceuticals Company | CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION |
AU2001253090A1 (en) | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of abeta protein production |
US20100009966A1 (en) * | 2001-04-11 | 2010-01-14 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of abeta protein production |
EP1289966A1 (en) | 2000-04-11 | 2003-03-12 | Bristol-Myers Squibb Pharma Company | SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
US6495589B2 (en) | 2000-04-28 | 2002-12-17 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
AU2001256733A1 (en) * | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
US6878363B2 (en) * | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
CA2410597A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
DE60140285D1 (de) | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
CN1386118A (zh) * | 2000-06-01 | 2002-12-18 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物 |
WO2002014277A1 (fr) * | 2000-08-10 | 2002-02-21 | Tanabe Seiyaku Co., Ltd. | Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci |
WO2002014276A1 (fr) * | 2000-08-10 | 2002-02-21 | Tanabe Seiyaku Co., Ltd. | Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese |
US6720330B2 (en) * | 2000-11-17 | 2004-04-13 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
WO2002070511A1 (en) | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
WO2002083134A1 (en) * | 2001-04-12 | 2002-10-24 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
US6911447B2 (en) * | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
DE50204789D1 (de) * | 2001-05-10 | 2005-12-08 | Solvay Pharm Gmbh | Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US20090062256A1 (en) * | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
IL159797A0 (en) | 2001-07-11 | 2004-06-20 | Palatin Technologies Inc | Linear and cyclic melanocortin receptor-specific peptides |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
US7125840B2 (en) | 2001-10-09 | 2006-10-24 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
US7396846B2 (en) | 2002-04-09 | 2008-07-08 | Eli Lilly And Company | Growth hormone secretagogues |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
US20040010010A1 (en) * | 2002-04-30 | 2004-01-15 | Ebetino Frank Hallock | Melanocortin receptor ligands |
US7026335B2 (en) * | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
TWI281914B (en) | 2002-05-29 | 2007-06-01 | Glaxo Group Ltd | Compounds |
WO2004007444A2 (en) | 2002-07-11 | 2004-01-22 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
CA2498272A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
TW200504033A (en) * | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
JP5105578B2 (ja) * | 2003-11-05 | 2012-12-26 | サーコード バイオサイエンス インコーポレイテッド | 細胞接着のモジュレーター |
CA2545644C (en) * | 2003-11-12 | 2011-11-01 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
US6974187B2 (en) * | 2004-01-28 | 2005-12-13 | Tachi-S Co., Ltd. | Vehicle seat structure |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
WO2006073361A1 (en) * | 2005-01-06 | 2006-07-13 | Astrazeneca Ab | Novel pyridine compounds |
KR101155335B1 (ko) * | 2005-01-07 | 2012-06-11 | 엘지전자 주식회사 | 이동통신 단말기의 멀티미디어 메시지 동작방법 |
CA2960117C (en) | 2005-05-17 | 2018-01-30 | Sarcode Bioscience Inc. | Lfa-1 antagonists for the treatment of eye disorders |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
US8791264B2 (en) * | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
US8937181B2 (en) * | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
EP2644618B1 (en) | 2007-02-09 | 2016-08-17 | Ocera Therapeutics, Inc. | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators |
US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
WO2009054914A1 (en) | 2007-10-19 | 2009-04-30 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
WO2012131090A1 (en) | 2011-03-31 | 2012-10-04 | Galderma Research & Development | Method for treatment of xeroderma pigmentosum |
AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
CN104910254B (zh) * | 2015-06-10 | 2018-05-01 | 华南农业大学 | 二肽Pro-Asp在促进动物肝细胞分泌IGF-1方面的应用 |
AU2016341884B2 (en) | 2015-10-19 | 2021-06-10 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
EP3448520A4 (en) * | 2016-04-29 | 2020-07-29 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
JP7217749B2 (ja) * | 2017-12-27 | 2023-02-03 | フラマ ソシエタ ペル アチオニ | ペプチド誘導体およびその治療活性 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3239345A (en) * | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
US4411890A (en) * | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
JPS5566375A (en) * | 1978-08-17 | 1980-05-19 | Hochiki Co | Bubble fire extinguishing chemical for hydrophile inflammable liquid |
US5206235A (en) * | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
US5317017A (en) * | 1992-09-30 | 1994-05-31 | Merck & Co., Inc. | N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release |
AU676525B2 (en) * | 1992-11-06 | 1997-03-13 | Merck & Co., Inc. | Substituted dipeptide analogs promote release of growth hormone |
PL176993B1 (pl) * | 1992-12-11 | 1999-08-31 | Merck & Co Inc | Nowe związki spiropiperydynowe oraz sposób ich wytwarzania |
US5284841A (en) * | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5545735A (en) * | 1993-10-04 | 1996-08-13 | Merck & Co., Inc. | Benzo-Fused Lactams promote release of growth hormone |
CA2173333A1 (en) * | 1993-10-19 | 1995-04-27 | Barry J. Gertz | Combination of bisphosphonates and growth hormone secretagogues |
-
1995
- 1995-05-29 AT AT95918123T patent/ATE288444T1/de not_active IP Right Cessation
- 1995-05-29 CA CA002220055A patent/CA2220055C/en not_active Expired - Fee Related
- 1995-05-29 US US08/973,268 patent/US5936089A/en not_active Expired - Fee Related
- 1995-05-29 EP EP95918123A patent/EP0828754B1/en not_active Expired - Lifetime
- 1995-05-29 ES ES95918123T patent/ES2235171T3/es not_active Expired - Lifetime
- 1995-05-29 JP JP08511175A patent/JP3133073B2/ja not_active Expired - Fee Related
- 1995-05-29 MX MX9709278A patent/MX9709278A/es not_active IP Right Cessation
- 1995-05-29 DE DE69533991T patent/DE69533991T2/de not_active Expired - Fee Related
- 1995-05-29 WO PCT/IB1995/000410 patent/WO1996038471A1/en active IP Right Grant
-
1996
- 1996-05-20 IL IL11833096A patent/IL118330A0/xx unknown
- 1996-05-28 CN CN96107637A patent/CN1143647A/zh active Pending
- 1996-05-28 KR KR1019960018325A patent/KR960041192A/ko not_active Application Discontinuation
- 1996-05-28 AU AU54554/96A patent/AU5455496A/en not_active Abandoned
- 1996-05-28 NO NO962162A patent/NO962162L/no unknown
-
1997
- 1997-11-28 FI FI974368A patent/FI974368A/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU5455496A (en) | 1996-12-12 |
EP0828754A1 (en) | 1998-03-18 |
NO962162D0 (no) | 1996-05-28 |
FI974368A0 (fi) | 1997-11-28 |
MX9709278A (es) | 1998-03-31 |
ES2235171T3 (es) | 2005-07-01 |
JPH10510511A (ja) | 1998-10-13 |
CA2220055C (en) | 2001-04-24 |
US5936089A (en) | 1999-08-10 |
CA2220055A1 (en) | 1996-12-05 |
DE69533991D1 (de) | 2005-03-10 |
FI974368A (fi) | 1997-11-28 |
DE69533991T2 (de) | 2006-04-13 |
IL118330A0 (en) | 1996-09-12 |
CN1143647A (zh) | 1997-02-26 |
JP3133073B2 (ja) | 2001-02-05 |
EP0828754B1 (en) | 2005-02-02 |
WO1996038471A1 (en) | 1996-12-05 |
ATE288444T1 (de) | 2005-02-15 |
KR960041192A (ko) | 1996-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO962162D0 (no) | Dipeptider som bevirker frigjöring av veksthormon | |
SE9604793D0 (sv) | New polymorphs | |
DK0833644T3 (da) | Farmaceutisk og diætetiske sammensætninger til forebyggelse og behandling af gastrointestinale sygdomme | |
AP9901478A0 (en) | Compounds for the treatment of ischemia. | |
DE69727922D1 (de) | Schnell zerfallende orale dosierungsform | |
ES2136723T3 (es) | Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante. | |
TW287949B (no) | ||
ATE400577T1 (de) | Anellierte dihydropyrane | |
PT741716E (pt) | Analogos de delta 12,13-iso-taxol sua utilizacao anti-neoplasica e composicoes farmaceuticas que os contem | |
HU9603042D0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration | |
ATE147981T1 (de) | Verabreichung von lamotrigin zur behandlung von neuro-aids | |
BR9509975A (pt) | Formulação farmacêutica | |
GB9712966D0 (en) | Novel chalcones | |
DE69420145D1 (de) | Behandlung präkanzeröser läsionen durch muramylpeptide | |
DE59510667D1 (de) | Pyridylthioverbindungen zur bekämpfung von helicobacter-bakterien | |
DK0711283T3 (da) | Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister | |
SE9600120D0 (sv) | Novel medical use | |
ATE215084T1 (de) | Imidazopyridin-azolidinone | |
DK0722325T3 (da) | Præparat til behandling eller forebyggelse af herpes | |
ES2091039T3 (es) | Nuevos bis-fenil-hexenos. | |
SE9404438D0 (sv) | New process | |
BG103859A (en) | The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions | |
AU6646894A (en) | 3-phenylureido-1,5-benzodiazepine-diones useful as gastrin or cck antagonists | |
SE9501773D0 (sv) | New use | |
NZ505085A (en) | Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi |